Padma Priya Manapragada MD, Abstract Co-Author: Nothing to Disclose

Devaki Shilpa Surasi MD, Abstract Co-Author: Nothing to Disclose

Fathima Fijula Palot Manzil MBBS, Abstract Co-Author: Nothing to Disclose

Janis Petrik O'Malley MD, Abstract Co-Author: Nothing to Disclose

Samuel E. Almodovar-Reteguis MD, Presenter: Nothing to Disclose

Main aims of this presentation are to review the physical/chemical properties of alpha particles, to discuss alpha particle emitters used in clinical practice and to provide an overview of newer treatment agents currently being developed. Radiation safety concerns regarding the use and disposal of  alpha emitter radiopharmaceuticals will also be reviewed.  

Introduction and overview of alpha decay and properties of alpha emitters. Historical perspective of alpha particle mediated therapies. Review of currently used alpha particle emitters, including clinical indications and their role in oncologic management. Specifically, this presentation will discuss clinical applications of Astatine 211, Bismuth 212, Actinium 225 , Radium 223 and Lead 212. Overview of future alpha particle emitter radiopharmaceuticals currently under development. Discussion of radiation safety considerations pertinent to alpha particle mediated therapies.  

This presentation will provide a better understanding of the growing role of alpha emitters, particularly  in the treatment of cancer, and radiation safety considerations pertinent to this therapies.

Manapragada, P, Surasi, D, Palot Manzil, F, O'Malley, J, Almodovar-Reteguis, S, Alpha Particles 2013: Current Perspectives on Alpha Particle Mediated Therapies.  Radiological Society of North America 2013 Scientific Assembly and Annual Meeting, December 1 - December 6, 2013 ,Chicago IL. http://archive.rsna.org/2013/13023749.html